{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:00:53Z","timestamp":1793325653120,"version":"4.5.0"},"reference-count":27,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":813,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1002\/jcph.116","type":"journal-article","created":{"date-parts":[[2013,6,10]],"date-time":"2013-06-10T11:36:43Z","timestamp":1370864203000},"page":"866-877","source":"Crossref","is-referenced-by-count":100,"title":["CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody\u2212Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies"],"prefix":"10.1002","volume":"53","author":[{"given":"Tae H.","family":"Han","sequence":"first","affiliation":[{"name":"Seattle Genetics, Inc.; Bothell; WA; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"University of Washington; Seattle; WA; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhakrishnan","family":"Ramchandren","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute; Detroit; MI; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center; Hackensack; NJ; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chen","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center; Duarte; CA; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Matous","sequence":"additional","affiliation":[{"name":"Colorado Blood Cancer Institute; Denver; CO; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Cooper","sequence":"additional","affiliation":[{"name":"St. Francis Hospital and Medical Center; Beech Grove; IN; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie E.","family":"Grove","sequence":"additional","affiliation":[{"name":"Seattle Genetics, Inc.; Bothell; WA; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Alley","sequence":"additional","affiliation":[{"name":"Seattle Genetics, Inc.; Bothell; WA; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel M.","family":"Lynch","sequence":"additional","affiliation":[{"name":"Seattle Genetics, Inc.; Bothell; WA; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen A.","family":"O'Connor","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies; Columbia University; New York; NY; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,6,10]]},"reference":[{"key":"10.1002\/jcph.116-BIB0001|jcph116-cit-0001","first-page":"32","article-title":"Antibody-targeted delivery of auristatin using SGN-35 leads to one to two logs greater intratumoral auristatin concentrations than non-targeted therapy [abstract]","volume":"2009","author":"Alley","year":"2009","journal-title":"AACR Meet Abstr."},{"key":"10.1002\/jcph.116-BIB0002|jcph116-cit-0002","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cbpa.2010.06.170","article-title":"Antibody-drug conjugates: targeted drug delivery for cancer","volume":"14","author":"Alley","year":"2010","journal-title":"Curr Opin Chem Biol."},{"key":"10.1002\/jcph.116-BIB0003|jcph116-cit-0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/bc9002019","article-title":"Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies","volume":"21","author":"Ducry","year":"2010","journal-title":"Bioconjug Chem."},{"key":"10.1002\/jcph.116-BIB0004|jcph116-cit-0004","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/clim.1998.4636","article-title":"CD30 in normal and neoplastic cells","volume":"90","author":"Chiarle","year":"1999","journal-title":"Clin Immunol."},{"key":"10.1002\/jcph.116-BIB0005|jcph116-cit-0005","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0092-8674(92)90180-K","article-title":"Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease","volume":"68","author":"Durkop","year":"1992","journal-title":"Cell."},{"key":"10.1002\/jcph.116-BIB0006|jcph116-cit-0006","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood-2007-07-099317","article-title":"A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies","volume":"111","author":"Bartlett","year":"2008","journal-title":"Blood."},{"key":"10.1002\/jcph.116-BIB0007|jcph116-cit-0007","first-page":"3736","article-title":"The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease","volume":"62","author":"Wahl","year":"2002","journal-title":"Cancer Res."},{"key":"10.1002\/jcph.116-BIB0008|jcph116-cit-0008","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat Biotechnol."},{"key":"10.1002\/jcph.116-BIB0009|jcph116-cit-0009","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood."},{"key":"10.1002\/jcph.116-BIB0010|jcph116-cit-0010","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","article-title":"Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate","volume":"16","author":"Okeley","year":"2010","journal-title":"Clin Cancer Res."},{"key":"10.1002\/jcph.116-BIB0011|jcph116-cit-0011","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1002\/jcph.116-BIB0012|jcph116-cit-0012","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol."},{"issue":"19","key":"10.1002\/jcph.116-BIB0013|jcph116-cit-0013","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1002\/jcph.116-BIB0014|jcph116-cit-0014","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/1078-0432.CCR-11-1425","article-title":"A phase I weekly dosing study of brentuximab vedotin in patients with relapsed\/refractory CD30-positive hematologic malignancies","volume":"18","author":"Fanale","year":"2012","journal-title":"Clin Cancer Res."},{"key":"10.1002\/jcph.116-BIB0015|jcph116-cit-0015","first-page":"PII-1","article-title":"The pharmacokinetics of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) [abstract]","volume":"91","author":"Han","year":"2012","journal-title":"Clin Pharmacol Ther."},{"key":"10.1002\/jcph.116-BIB0016|jcph116-cit-0016","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1177\/00912700122012751","article-title":"Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse","volume":"41","author":"Dowell","year":"2001","journal-title":"J Clin Pharmacol."},{"key":"10.1002\/jcph.116-BIB0017|jcph116-cit-0017","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00280-011-1817-3","article-title":"Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer","volume":"69","author":"Girish","year":"2012","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1002\/jcph.116-BIB0018|jcph116-cit-0018","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s10637-011-9670-0","article-title":"Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate. In adult patients with relapsed\/refractory acute myeloid leukemia","volume":"30","author":"Lapusan","year":"2012","journal-title":"Invest New Drugs."},{"key":"10.1002\/jcph.116-BIB0019|jcph116-cit-0019","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.2108","article-title":"Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates","volume":"30","author":"Shen","year":"2012","journal-title":"Nat Biotechnol."},{"key":"10.1002\/jcph.116-BIB0020|jcph116-cit-0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2009.308","article-title":"Therapeutic protein-drug interactions and implications for drug development","volume":"87","author":"Huang","year":"2010","journal-title":"Clin Pharmacol Ther."},{"key":"10.1002\/jcph.116-BIB0021|jcph116-cit-0021","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1177\/0091270007306958","article-title":"Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check","volume":"47","author":"Seitz","year":"2007","journal-title":"J Clin Pharmacol."},{"key":"10.1002\/jcph.116-BIB0022|jcph116-cit-0022","unstructured":"ADCETRIS\u00ae [package insert] 2012"},{"key":"10.1002\/jcph.116-BIB0023|jcph116-cit-0023","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1177\/0091270007308616","article-title":"Drug interaction studies of therapeutic proteins or monoclonal antibodies","volume":"47","author":"Mahmood","year":"2007","journal-title":"J Clin Pharmacol."},{"issue":"24 Suppl.","key":"10.1002\/jcph.116-BIB0024|jcph116-cit-0024","article-title":"Pharmacokinetics (PK) of trastuzumab-DM1 (T-DM1) and paclitaxel (T) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen [abstract]","volume":"70","author":"Lu","year":"2010","journal-title":"Cancer Res."},{"key":"10.1002\/jcph.116-BIB0025|jcph116-cit-0025","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/clpt.1993.25","article-title":"A potentially hazardous interaction between erythromycin and midazolam","volume":"53","author":"Olkkola","year":"1993","journal-title":"Clin Pharmacol Ther."},{"key":"10.1002\/jcph.116-BIB0026|jcph116-cit-0026","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","article-title":"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole","volume":"55","author":"Olkkola","year":"1994","journal-title":"Clin Pharmacol Ther."},{"key":"10.1002\/jcph.116-BIB0027|jcph116-cit-0027","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0169-409X(02)00171-0","article-title":"Drug-drug interaction mediated by inhibition and induction of P-glycoprotein","volume":"55","author":"Lin","year":"2003","journal-title":"Adv Drug Deliv Rev."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.116","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/jcph.116\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:02:30Z","timestamp":1657803750000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,10]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.116","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6,10]]}}}